Abstract 1162P
Background
Tumor acidity negatively regulates tumor-specific effector T cells in the tumor microenvironment. Conflicting results emerged on the impact of PPI on the efficacy of ICB.
Methods
A retrospective analysis was conducted on patients (pts) with metastatic melanoma treated with ICB between 2019 and 2020 at the Christie NHS Foundation Trust. Data on demographics, sites of disease, performance status (PS), comorbidities, types of therapy, progression-free (PFS), and overall survival (OS) were collected. Statistical analyses were performed with univariable and multivariable Cox regression models. The aim was to define the association between PPI exposure (defined as 30 days before or after the initiation of ICB and for at least 21 days concomitant with ICB) and PFS, and OS.
Results
Data was collected on 189 pts with a median age of 60 years; 57.14% were male, 88% had ECOG PS 0/1, 17% were BRAF mutant, 28% had elevated serum LDH, and 28.5% had brain metastases. 162 (86%) pts received ICB as their first line of treatment for advanced disease. The majority of pts (92%) received ipilimumab and nivolumab, and 8% received pembrolizumab. 83 (44%) of pts were identified as PPI users with a median duration of PPI use concomitantly with ICB of 365 days (range 21-1976 days). PPI use was significantly associated with longer median PFS (not reached vs. 7.3 months, Hazard ratio (HR):0.53, 95%CI:0.35-0.79, p=0.002) and longer median OS (not reached vs. 17.2 months, HR:0.47, 95%CI:0.30-0.73, p=0.001). In a multivariable regression analysis accounting for age, gender, PS, Charlson comorbidity score, BRAF status, elevated LDH, brain and liver metastases, and line of treatment, the favorable impact of PPI use on PFS (HR:0.53, 95%CI:0.35-0.81, p=0.003) and OS (HR: 0.43, 95%CI:0.27-0.69, p<0.0001) was maintained.
Conclusions
Exposure to PPI for more than 21 days at the initiation of ICB mediates better clinical outcomes. Our findings suggest that the duration and timing of PPI use should be considered when investigating the impact on ICB outcomes. Prospective studies are required to test the priming effect of PPI on tumors with acidic microenvironments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Christie NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13
1140P - Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Presenter: Emilie Gerard
Session: Poster session 13
1141P - Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Presenter: Elena Croce
Session: Poster session 13
1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Presenter: Marlies Wakkee
Session: Poster session 13
1143P - Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Presenter: Daniela Esposito
Session: Poster session 13
1144P - High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
Presenter: Rahul Ladwa
Session: Poster session 13
1145P - Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Presenter: Juergen Becker
Session: Poster session 13
1146P - Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
Presenter: Giovanni Grignani
Session: Poster session 13
1148P - Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Presenter: Astrid Blom Fily
Session: Poster session 13